Showing posts with label Ibrutinib. Show all posts
Showing posts with label Ibrutinib. Show all posts
Saturday, August 11, 2018

Researchers find leukemia and lymphoma drug may benefit glioblastoma patients

›
In continuation of my update on  ibrutinib New Cleveland Clinic research shows for the first time that ibrutinib, an FDA-approved drug...
Saturday, July 28, 2018

FDA-approved drug for lymphoma and leukemia may help treat common type of brain tumor

›
In continuation of my update on  Ibrutinib New Cleveland Clinic research shows for the first time that ibrutinib , an FDA-...
Tuesday, September 20, 2016

Ibrutinib: Indication of added benefit in one of three therapeutic indications...

›
In continuation of my update on Ibrutinib Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the tre...
Wednesday, January 27, 2016

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

›
In continuation of my update on  ibrutinib A multi-center, international, randomized, Phase III study of older untreated patients with...
Thursday, September 24, 2015

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

›
In continuation of my update on Ibrutinib Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA®) improved p...
Thursday, July 30, 2015

Newly approved drug for rare blood cancer shows sustained benefit for 2 years

›
In continuation of my update on Ibrutinib   We know that,  Ibrutinib      also known as  PCI-32765  and marketed under t...
Tuesday, July 23, 2013

New Drug Application Submitted to U.S. FDA for Ibrutinib in the Treatment of Two B-Cell Malignancies

›
We know that,  Ibrutinib , also known as PCI-32765, is an experimental drug candidate for the treatment of various types of cancer. It is...